- ISIN
- US76155X1000
- CUSIP
- 76155X100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 13, 2020
Highlights
- Market Cap
- $32.85B
- Enterprise Value
- $32.58B
- EPS (TTM)
- -$7.17
- Gross Profit (TTM)
- -$4.70M
- EBITDA (TTM)
- -$1.34B
- Year Range
- $34.00 - $166.84
- Target Price
- $154.80
- ROA (TTM)
- -60.86%
- ROE (TTM)
- -91.45%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RVMD Performance Chart
Revolution Medicines, Inc. (RVMD) is up 108.2% since the beginning of the year. At $166 per share, RVMD is trading just below its 52-week high of $167. Investors who bought $1,000 worth of RVMD shares 5 years ago would now be looking at an investment worth $5,047.
Loading charts...
Returns By Period
Revolution Medicines, Inc. (RVMD) has returned 108.17% so far this year and 318.08% over the past 12 months.
Revolution Medicines, Inc.
- 1D
- 1.73%
- 1M
- 9.40%
- YTD
- 108.17%
- 6M
- 105.77%
- 1Y
- 318.08%
- 3Y*
- 86.60%
- 5Y*
- 38.23%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
RVMD Monthly Returns History
Based on dividend-adjusted daily data since Feb 13, 2020, RVMD's average daily return is +0.20%, while the average monthly return is +3.63%. At this rate, an investment would double in approximately 1.6 years.
Historically, 61% of months were positive and 39% were negative. The best month was Apr 2026 with a return of +48.2%, while the worst month was Mar 2020 at -29.9%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 4 months.
On a daily basis, RVMD closed higher 51% of trading days. The best single day was Apr 13, 2026 with a return of +41.4%, while the worst single day was Oct 23, 2023 at -34.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.72% | 5.23% | -4.68% | 48.20% | 9.27% | 5.29% | 108.17% | ||||||
| 2025 | -1.81% | -5.15% | -13.21% | 14.20% | -2.43% | -6.62% | 1.30% | 1.88% | 22.99% | 26.00% | 32.15% | 2.43% | 82.10% |
| 2024 | -3.24% | 6.23% | 9.33% | 15.67% | 2.82% | 1.25% | 17.60% | -6.60% | 6.38% | 17.97% | 8.13% | -24.39% | 52.51% |
| 2023 | 12.26% | 0.07% | -19.06% | 8.45% | 6.13% | 7.30% | -1.87% | 29.41% | -18.52% | -28.47% | 17.83% | 22.93% | 20.40% |
| 2022 | -14.50% | -12.08% | 34.83% | -21.72% | -14.97% | 14.78% | 15.91% | -7.79% | -5.33% | 2.74% | 16.44% | 0.97% | -5.36% |
| 2021 | 6.44% | 8.40% | 0.44% | -27.66% | -9.88% | 6.12% | -9.77% | 1.57% | -5.43% | 6.98% | -6.01% | -9.00% | -36.42% |
Benchmark Metrics
Revolution Medicines, Inc. has an annualized alpha of 39.26%, beta of 1.11, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since February 13, 2020.
- This stock captured 151.77% of S&P 500 Index gains but only 85.18% of its losses - a favorable profile for investors.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 39.26%
- Beta
- 1.11
- R²
- 0.12
- Upside Capture
- 151.77%
- Downside Capture
- 85.18%
Return for Risk
Risk / Return Rank
RVMD ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Revolution Medicines, Inc. (RVMD) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RVMD | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.74 | ||
| Sortino ratioReturn per unit of downside risk | +3.05 | ||
| Omega ratioGain probability vs. loss probability | 1.82 | 1.37 | +0.45 |
| Calmar ratioReturn relative to maximum drawdown | 12.84 | 2.78 | +10.06 |
| Martin ratioReturn relative to average drawdown | 30.76 | 12.44 | +18.32 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Revolution Medicines, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Revolution Medicines, Inc. was 73.29%, occurring on May 12, 2022. Recovery took 622 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -73.29%May 2022 | 1y 3mo | 2y 5mo | 3y 8moFeb 2021 - Nov 2024 |
2025 selloff2025 | -48.63%Apr 2025 | 4mo 27d | 7mo 2d | 11mo 29dNov 2024 - Nov 2025 |
2020 bear market2020 | -42.53%Jul 2020 | 1mo 7d | 2mo 8d | 3mo 15dJun 2020 - Oct 2020 |
COVID crash2020 | -42.34%Apr 2020 | 27d | 1mo 4d | 2mo 1dMar 2020 - May 2020 |
2020 bear market2020 | -33.63%Oct 2020 | 11d | 3mo 5d | 3mo 16dOct 2020 - Feb 2021 |
Drawdown Indicators
| RVMD | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -73.29% | -56.78% | -16.51% |
Max Drawdown (1Y)Largest decline over 1 year | -24.95% | -9.10% | -15.85% |
Max Drawdown (3Y)Largest decline over 3 years | -48.63% | -18.90% | -29.73% |
Max Drawdown (5Y)Largest decline over 5 years | -56.85% | -25.43% | -31.42% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | -35.58% | -10.71% | -24.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.40% | 2.03% | +8.37% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Revolution Medicines, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Revolution Medicines, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RVMD in comparison with other companies in the Biotechnology industry. Currently, RVMD has a P/B value of 21.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RVMD
Add Revolution Medicines, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RVMD